The gold standard of diagnosis for nonmelanoma and melanoma skin cancer has been skin biopsy with routine paraffin embedded hematoxylin and eosin histopathology. This practice is frequently carried out on suspicious lesions to rule out a malignant process. Therefore, as a result, many biopsies are done on benign lesions. Unlike other fields of medicine that rely on noninvasive imaging modalities, the use of imaging devices in dermatology has not been as robust. This has been mainly due to the limited resolution offered by imaging devices that is needed to detect malignant changes in the cutaneous layers. However, the demand for more efficient in vivo and ex vivo imaging tools to reduce the amount of biopsies have led to new areas of investigation using noninvasive modalities to augment the clinical diagnosis of skin cancer. The use of noninvasive imaging both in vivo and ex vivo has the potential to increase efficiency of diagnosis and management, decrease healthcare cost, improve clinical care and enhance patient satisfaction. About 25% of all malignant neoplasms in humans are nonmelanoma skin cancers (NMSC). Approximately 3.5 million new cases of NMSC are diagnosed in the USA every year, and the incidence rate is increasing [1]. Between 1992 and 2006 the rate has increased by 4.2% per year. Of these cases, about 70% are basal cell carcinomas (BCCs). BCC is the most common skin malignancy and the most common malignancy worldwide. The rise of NMSC incidence is multifactorial; related to ultraviolet light exposure, recreational behavior, life expectancy and registration of skin cancer diagnosis. As such, BCC occurs most frequently on the head and neck regions. Women tend to have a greater frequency of BCC on the lower extremities while men have more occurring on the ear. The overall incidence is also increasing with rates estimated to have risen between 20 and 80% with similar increases noted worldwide and tend to increase with increasing age [2]. The mortality rates from NMSC remain low in comparison to other types of malignancies, but can cause significant morbidity for the patient.
KEYWORDSBCC mainly causes local destruction with metastasis or spread extremely rare and can be thought of in terms of high or low risk. Mortality from BCC is quite rare and can occur in immunocompromised patients. Cases of metastatic BCC are more likely from patients with basal cell nevus syndrome or tumors with aggressive histologic patterns (morpheaform/infiltrating). Perineural invasion is also an indicator of aggressive disease [3].Basal cell carcinoma of the integumentary system are usually detected on a routine physician clinical exam and diagnosed by histological analysis via skin biopsy. The use of skin biopsy to diagnose skin malignancies is considered the gold standard of diagnosis and a benchmark used to base other diagnostic modalities against. However, in patients with an extensive history of basal cell carcinomas or widespread actinic damage multiple biopsies may not be practical or cosmetically appreciable.For reprin...